Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.
about
The Multiple Sclerosis (MS) Genetic Risk Factors Indicate both Acquired and Innate Immune Cell Subsets Contribute to MS Pathogenesis and Identify Novel Therapeutic Opportunities.Dimethyl fumarate alters B-cell memory and cytokine production in MS patientsDimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count.Effects of fumarates on inflammatory human astrocyte responses and oligodendrocyte differentiation.Analysis of IL-6, IL-1β and TNF-α production in monocytes isolated from multiple sclerosis patients treated with disease modifying drugs.Donor variability may mask dimethyl fumarate's effects on nuclear factor E2-related factor 2 in human peripheral blood mononuclear cells.Deciphering the Role of B Cells in Multiple Sclerosis-Towards Specific Targeting of Pathogenic Function.Role of Immunological Memory Cells as a Therapeutic Target in Multiple Sclerosis.Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod.Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis.Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird's Eye View.Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients.Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment.The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis.Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple SclerosisDimethyl fumarate as a first- vs second-line therapy in MS: Focus on B cellsRegulatory B and T lymphocytes in multiple sclerosis: friends or foes?
P2860
Q33572483-8EA4050E-73FB-45F8-93CD-17717E32352CQ33646238-E7B45B1D-4340-42D1-AD2B-4BC6366C8FEEQ38798794-05CAF645-DACB-4E7E-A6DF-E4D082C42F4AQ42229875-6872E275-BFF7-46A8-889A-2C2B3F13A2B6Q42238962-8FD054CC-EC6C-41C2-ADCE-AD3BFF020EE8Q44853889-1AA60473-CAF8-49C3-BE76-796834335E0DQ47102132-3A782D11-BD80-4A79-B977-350E203130E5Q47130362-EED60509-4B99-466B-8312-3E67B7560AC3Q49354326-36391117-4652-4262-817B-FAA3E557CE90Q49800939-80C642C5-8F7E-488C-BDC1-AFCABD0F2642Q49884884-1D29C8F5-9D29-4BEF-AB8D-C24A7A4419C3Q55117400-8789E055-C515-4F1C-B490-EB9749916AD7Q55396042-44B0B706-B24C-42A2-B04C-AE9563CD6AF6Q55439580-BD4B86A3-50BA-4A8F-B88E-F279A309C085Q57470698-CB9F8B5A-B730-4582-8838-9FEB79216BC1Q57814499-FD5C1C1F-D9FE-4DE2-A3C5-93EF19B1DB7AQ58555322-4299CEC2-BF9F-48DC-B306-7249F7982DC4
P2860
Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Dimethyl Fumarate Treatment Me ...... ients with Multiple Sclerosis.
@en
Dimethyl Fumarate Treatment Me ...... ients with Multiple Sclerosis.
@nl
type
label
Dimethyl Fumarate Treatment Me ...... ients with Multiple Sclerosis.
@en
Dimethyl Fumarate Treatment Me ...... ients with Multiple Sclerosis.
@nl
prefLabel
Dimethyl Fumarate Treatment Me ...... ients with Multiple Sclerosis.
@en
Dimethyl Fumarate Treatment Me ...... ients with Multiple Sclerosis.
@nl
P2093
P2860
P50
P356
P1476
Dimethyl Fumarate Treatment Me ...... ients with Multiple Sclerosis.
@en
P2093
P2860
P304
P356
10.4049/JIMMUNOL.1601649
P407
P577
2016-12-14T00:00:00Z